See more : PageGroup plc (MPGPF) Income Statement Analysis – Financial Results
Complete financial analysis of Infinity Pharmaceuticals, Inc. (INFI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Infinity Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- COPRO-HOLDINGS. Co., Ltd. (7059.T) Income Statement Analysis – Financial Results
- AnalytixInsight Inc. (ATIXF) Income Statement Analysis – Financial Results
- Park Street A/S (PARKST-A.CO) Income Statement Analysis – Financial Results
- Geomega Resources Inc. (GMA.V) Income Statement Analysis – Financial Results
- Idorsia Ltd (0RQE.L) Income Statement Analysis – Financial Results
Infinity Pharmaceuticals, Inc. (INFI)
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59M | 1.86M | 1.72M | 3.05M | 22.15M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 34.84M | 51.56M | 49.83M | 41.32M | 41.13M | 36.26M | 13.08M | 6.20M | 3.10M | 400.00K | 0.00 |
| Cost of Revenue | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.11M | 29.44M | 31.67M | 35.49M | 24.86M | 9.90M | 7.87M | 2.80M | 1.30M | 200.00K | 0.00 |
| Gross Profit | 1.03M | 738.00K | 682.00K | -4.26M | 22.08M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 9.73M | 22.12M | 18.16M | 5.83M | 16.28M | 26.37M | 5.20M | 3.40M | 1.80M | 200.00K | 0.00 |
| Gross Profit Ratio | 39.72% | 39.72% | 39.67% | -139.69% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 27.93% | 42.91% | 36.44% | 14.10% | 39.57% | 72.71% | 39.78% | 54.84% | 58.06% | 50.00% | 0.00% |
| Research & Development | 32.41M | 31.65M | 26.76M | 27.12M | 19.76M | 20.83M | 119.61M | 199.11M | 143.63M | 99.76M | 118.60M | 108.58M | 99.23M | 77.86M | 47.47M | 33.79M | 35.79M | 3.92M | 4.30M | 2.55M | 6.22M | 12.98M | 8.93M | 3.54M | 5.10M | 4.10M | 2.60M | 600.00K |
| General & Administrative | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 0.00 | 21.07M | 19.46M | 16.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00M | 2.50M | 1.60M | 600.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 22.72M | 21.07M | 19.46M | 16.84M | 14.03M | 9.46M | 15.07M | 14.10M | 13.96M | 12.27M | 11.02M | 8.41M | 4.44M | 5.00M | 2.50M | 1.60M | 600.00K |
| Other Expenses | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | -6.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 45.82M | 39.18M | 41.41M | 34.01M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 24.72M | 19.41M | 17.03M | 70.21M | 30.92M | 30.55M | 8.65M | 10.00M | 6.70M | 4.20M | 1.20M |
| Cost & Expenses | 47.44M | 46.94M | 40.22M | 48.71M | 34.08M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 49.83M | 48.85M | 48.70M | 105.69M | 55.78M | 40.45M | 16.52M | 12.80M | 8.00M | 4.40M | 1.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.00K | 0.00 | 559.00K | 326.75K | 463.01K | 2.04M | 3.34M | 6.58M | 2.46M | 2.02M | 1.42M | 1.80M | 2.18M | 3.53M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 180.00K | 180.00K | 2.45M | 2.56M | 93.00K | 1.01M | 1.23M | 1.37M | 9.65M | 0.00 | 1.91M | 1.84M | 1.91M | 1.30M | 21.37K | 188.04K | 1.51M | 4.81K | 6.14K | 40.75K | 144.47K | 279.58K | 1.53M | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 458.00K | 480.00K | 483.00K | 219.00K | 191.00K | 1.72M | 3.42M | 2.29M | 1.77M | 1.82M | 1.64M | 2.10M | 2.18M | 2.15M | 1.97M | 2.81M | 3.69M | 6.23M | 6.71M | 5.29M | 57.04M | 12.60M | 13.20M | 671.71K | 600.00K | 200.00K | 0.00 | 0.00 |
| EBITDA | -44.84M | -44.60M | -38.01M | -45.66M | -11.74M | -43.33M | -30.89M | -127.11M | -7.58M | -125.85M | -52.81M | -36.10M | -48.97B | -47.77B | 24.45M | -20.48M | -26.76B | -16.04B | 9.60M | 8.24M | -64.38B | -14.65B | 17.89M | -2.64M | -5.40M | -4.60M | -4.00M | -1.20M |
| EBITDA Ratio | -1,729.43% | -2,400.59% | -2,211.40% | -1,497.67% | -53.00% | -722.12% | -764.34% | -116.54% | -4.60% | 0.00% | -205.82% | -38.91% | -66.98% | -63.66% | 29.30% | -83.48% | -116.38% | -9.51% | 18.62% | 16.54% | 106.23% | -4.95% | 49.32% | -20.20% | -87.10% | -148.39% | -1,000.00% | 0.00% |
| Operating Income | -44.84M | -45.08M | -38.50M | -45.66M | -11.93M | -36.45M | -30.89M | -127.11M | -7.92M | -127.68M | -52.81M | -38.53M | -48.97M | -47.77M | 19.14M | -23.29M | -26.76M | -16.04M | 2.72M | -748.49K | -64.38M | -14.65M | -4.18M | -3.45M | -6.60M | -4.80M | -4.00M | -1.20M |
| Operating Income Ratio | -1,729.43% | -2,426.43% | -2,239.50% | -1,497.67% | -53.87% | -607.42% | -164.99% | -116.54% | -4.80% | 0.00% | -112.09% | -41.53% | -68.65% | -96.44% | 22.94% | -94.92% | -144.70% | -46.03% | 5.27% | -1.50% | -155.83% | -35.61% | -11.53% | -26.36% | -106.45% | -154.84% | -1,000.00% | 0.00% |
| Total Other Income/Expenses | 475.00K | -179.00K | -2.00M | -1.45M | 676.00K | -6.11M | 790.00K | -933.00K | -9.31M | 896.00K | -1.16M | -1.51M | -713.27K | 14.94M | 4.52M | 6.39M | -598.01K | 2.33M | 1.24M | -1.82M | -51.23M | 3.50B | -8.87M | -133.92K | 300.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -44.37M | -45.26M | -40.49M | -47.11M | -11.25M | -42.55M | -30.10M | -128.04M | -17.23M | -126.78M | -53.96M | -40.04M | -49.68M | -32.83M | 23.65M | -16.90M | -27.36M | -13.71M | 3.96M | -2.57M | -115.61M | -14.66M | -13.05M | -3.58M | -6.30M | -4.80M | -4.00M | -1.20M |
| Income Before Tax Ratio | -1,711.11% | -2,436.06% | -2,355.56% | -1,545.13% | -50.81% | -709.17% | -160.77% | -117.40% | -10.44% | 0.00% | -114.54% | -43.16% | -69.65% | -66.28% | 28.35% | -68.87% | -147.94% | -39.35% | 7.68% | -5.16% | -279.82% | -35.64% | -35.98% | -27.39% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| Income Tax Expense | -1.11M | 180.00K | 2.45M | -54.00K | 769.00K | -720.00K | -2.19M | 335.00K | 183.00K | 0.00 | 1.91M | 326.75K | -700.32K | -329.57K | 21.37K | 0.00 | 1.09M | 13.24K | 55.58K | 65.59K | -2.27M | -3.50M | 7.51M | -76.72K | 600.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -43.26M | -45.44M | -42.94M | -47.06M | -11.25M | -41.83M | -30.10M | -128.38M | -17.42M | -126.78M | -53.96M | -40.04M | -48.98M | -32.51M | 23.65M | -16.90M | -28.45M | -14.16M | 3.90M | 1.06M | -62.11M | -11.15M | -11.70M | -3.37M | -6.30M | -4.80M | -4.00M | -1.20M |
| Net Income Ratio | -1,668.18% | -2,445.75% | -2,497.79% | -1,543.36% | -50.81% | -697.17% | -160.77% | -117.70% | -10.56% | 0.00% | -114.54% | -43.16% | -68.67% | -65.62% | 28.35% | -68.87% | -153.82% | -40.66% | 7.57% | 2.13% | -150.34% | -27.10% | -32.25% | -25.78% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| EPS | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.17 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| EPS Diluted | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.14 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| Weighted Avg Shares Out | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.24M | 19.51M | 7.46M | 2.14M | 1.82M | 1.29M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
| Weighted Avg Shares Out (Dil) | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.77M | 19.51M | 7.46M | 2.14M | 6.54M | 6.08M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options
NEW YORK , Sept. 2, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI) and reminds investors of the October 16, 2023...
Infinity Pharmaceuticals, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in in the United States District Court for the District of Massachusetts against Infinity Pharmaceuticals, Inc.
UPCOMING LE AD PLAINTIFF DEADLINE IS OCTOBER 16, 2023 NEW YORK , Sept. 1, 2023 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a class action lawsuit has been filed against Infinity Pharmaceuticals, Inc. ("Infinity" or...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b) and...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI). Such investors are advised to contact Robert S.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
NEW YORK , Aug. 27, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the...
INFINITY SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options
NEW YORK , Aug. 26, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI) and reminds investors of the October 16, 2023...
Source: https://incomestatements.info
Category: Stock Reports